What are general colorectal cancer surveillance considerations for Crohn's disease versus ulcerative colitis?

• A. UC and Crohn's with colonic involvement both increase risk; surveillance depends on extent and duration; PSC with UC increases risk; immunomodulators do not negate risk
• B. There is no cancer risk in either disease
• C. Only UC increases risk; Crohn's does not
• D. Cancer risk is determined solely by age

Answer: (A)

The main concept here is that colorectal cancer risk in inflammatory bowel disease is driven by the amount and duration of colonic inflammation, and surveillance must be tailored to how much of the colon is involved and how long the disease has been present. Ulcerative colitis and Crohn's disease with colonic involvement both raise cancer risk, and the longer the disease has affected the colon, the higher that risk becomes. When primary sclerosing cholangitis is present with ulcerative colitis, the risk goes up even more, so surveillance is intensified in that scenario.

Understanding the differences helps: UC affects the colon in a continuous way, and the risk accumulates over years of colonic exposure to inflammation. In Crohn's, if only the small bowel is involved, colorectal cancer risk is not as elevated; Crohn’s with colonic (Crohn’s colitis) behaves similarly to UC in terms of risk factors, so surveillance decisions follow extent and duration. Immunomodulators or biologics don’t erase the risk—they reduce inflammation and may lower ongoing risk, but they don’t eliminate cancer risk, so ongoing surveillance remains important.

That’s why the best approach is to base surveillance on how much of the colon is involved and for how long the disease has been present, with especially careful monitoring if PSC is also present. The other statements don’t reflect these nuances: cancer risk is real in these diseases, Crohn’s with colonic involvement does increase risk, and age alone isn’t the determining factor.